Compare Fubotv Inc (FUBO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs TG Therapeutics Inc — how do they compare? Fubotv Inc trades at $9.63 (market cap $1.06B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 7.2× Fubotv Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| FUBO | TGTX | |
|---|---|---|
Market Cap | $1.06B | $7.64B |
Sector | Technology | Health |
52-Week High | $54.72 | $59.06 |
52-Week Low | $8.09 | $26.94 |
Enterprise Value | $1.23B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.45, up 0.96% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion, beating expectations, and raised its full-year adjusted EBITDA outlook to $90–$100 million. Valuation ratios appear attractive with a P/E of 2.53 and P/S of 0.19, while recent leadership changes include the appointment of former Disney executive Alisa Bowen as CEO.
The outlook is positive as FUBO shows improving financials and strategic partnerships, but risks include persistent net losses and high debt. Analyst consensus is a Buy with a $15.33 price target, suggesting significant upside potential if profitability goals are met.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
